Early biomarker signals from IMNN-001 strengthen the scientific rationale for IMUNON's pivotal Phase III ovarian cancer trial, with future data expected to determine whether the findings translate into clinical benefit.
Early biomarker signals from IMNN-001 strengthen the scientific rationale for IMUNON's pivotal Phase III ovarian cancer trial, with future data expected to determine whether the findings translate into clinical benefit.